Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting

American Journal of Cardiology

Volumn 113, Issue 4, 2014, Pages 650-654

  Carley, Blake ^a   Griesbach, Sara ^a   Larson, Tonja ^a   Krueger, Kori ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTITHROMBOCYTIC AGENT; CARVEDILOL; DABIGATRAN; DILTIAZEM; DRONEDARONE; ENOXAPARIN; GLYCOPROTEIN P INHIBITOR; LEPIRUDIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; DRUG UTILIZATION; FEMALE; GROUP PRACTICE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; OFF LABEL DRUG USE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VALVULAR HEART DISEASE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; GROUP PRACTICE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES;

EID: 84893462792     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.11.008     Document Type: Article

References (13)

1. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
2. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijna, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation Chest 138 2010 1093 1100
3. FDA Drug Safety Communication: Pradaxa (Dabigatran Etexilate Mesylate) Should Not Be Used in Patients With Mechanical Prosthetic Heart Valves December 12 2012 Food and Drug Administration U.S Available at: http://www.fda.gov/Drugs/ DrugSafety/ucm332912.htm Accessed February 21, 2013
4. Pradaxa® (Dabigatran) [package Insert United States] 2012 Boehringer-Ingelheim Pharmaceuticals, Inc Ridgefield, CT
5. Pradaxa® (Dabigatran) [package Insert Worldwide] 2012 Boehringer-Ingelheim Rhein, Germany
6. K.P. Garnock-Jones Dabigatran etexilate: a review of its use in prevention of stroke and systemic embolism in patients with atrial fibrillation Am J Cardiovasc Drugs 11 2011 57 72
7. J.R. Horn, and P.D. Hansten Dabigatran: a new oral anticoagulant Pharm Times 76 2010 Online only. Available at: http://www.pharmacytimes.com/ publications/issue/2010/December2010/DrugInteractions-1210 Accessed February 21, 2013
8. S. Hariharan, and R. Madabushi Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment J Clin Pharmacol 52 2012 119S 125S
9. D.R. Mack, and J.J. Kim Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation Ann Pharmacother 46 2012 1105 1110
10. G. Guyatt, E.A. Akl, M. Crowther, D.D. Gutterman, H.J. Schuunemann, and American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 2012 7S 47S
11. D.E. Singer, G.W. Albers, J.E. Dalen, M.C. Fang, A.S. Go, J.L. Halperin, G.Y. Lip, W.J. Manning, and American College of Chest Physicians Antithrombotic therapy in atrial fibrillation: American College of Chest physicians evidence-based clinical practice guidelines (8th edition) Chest 133 2008 546S 592S
12. Institute for Safe Medication Practices. Quarter Watch Monitoring FDA MedWatch Reports. Anticoagulants the Leading Reported Drug Risk in 2011. Horsham, PA: ISMP; May 31, 2012. Available at: http://www.ismp.org/quarterwatch/ pdfs/2011Q4.pdf. Accessed February 21, 2013.
13. P. Harper, L. Young, and E. Merriman Bleeding risk with dabigatran in the frail elderly N Engl J Med 366 2012 864 866